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Migraine is a difficult disorder to identify with regard to its
pathophysiological mechanisms, and its treatment has been primarily
difficult owing to interindividual differences. Substantial rates of
nonresponsiveness to medications are common, making migraine
treatment complicated. In this review, we systematically analyzed
recent studies concerning neuroimaging findings regarding the
neurophysiology of migraine. We linked the current imaging research
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with anecdotal evidence from interindividual factors such as duration
and pain intensity of migraine, age, gender, hormonal interplay, and
genetics. These factors suggested the use of nonpharmacological
therapies such as transcranial magnetic stimulation, transcranial
direct current stimulation, and placebo therapy for the treatment of
migraine. Finally, we discussed how interindividual differences are
related to such nondrug treatments.
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1

Introduction

Migraine is a widespread, immobilizing disease
that is characterized by recurring moderate-tosevere headaches and constitutes a significant
healthcare or social setback because it considerably
influences people’s quality of life [1]. Migraine
occurs in approximately 12% of the general
population [2] and has a higher prevalence in
females [3]; in the United States alone, its estimated

healthcare costs equal to approximately $1 billion
[4]. Migraine is triggered by visual, olfactory, and
auditory stimuli [5]. Such sensory hypersensitivities
are present during and between migraine attacks,
are definitely unique to migraine, and are not
found in other headache or pain disorders. The
suffering and debilitation caused by migraine
are extensive, affecting every aspect of a
migraineur’s life, and migraine is the fifth leading
cause of emergency room visits in the United
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States alone [6]. Nowadays, researchers have
suggested that the development and maintenance
of migraine may be owing to neurovascular
abnormalities, and are related to the dysfunction
of the central nervous system [7].
Although numerous pharmacological choices
are available to treat migraine, none of them
is ideal for most individuals. For example, acetaminophen [8] and nonsteroidal anti-inflammatory
drugs (NSAIDs) [9] are the first line of efficacious
treatment for migraine. NSAID-triptan combinations [10, 11], dihydroergotamine [12],
nonopioid combination analgesics [13], and few
antiemetics [14] provide additional evidence-based
choices. Although opioid-containing combination
analgesics can help a specific group of patients,
they should not be utilized frequently because
of risk of overuse and addiction issues [15]. The
opioid crisis is of increasing importance both
clinically and politically because two of three drug
overdose deaths involve opioid use [16]. Opioids
were initially prescribed for postsurgical and
cancer-related pain conditions [17]. At the end of
the 20th century, opioid prescriptions for treating
all forms of pain became the standard care [17].
This significant increase in opioid prescriptions
led to opioid use disorder, which now affects
approximately 2 million individuals in the United
States, and opioid-related deaths [18]. Although
opioids are prescribed for managing various forms
of pain, evidence of their long-term efficacy and
safety is limited [17].
To alleviate the opioid crisis, practitioners are
encouraged to consider nondrug options [19] for
the treatment of migraine, especially in patients
who encounter side effects or drug interactions,
are treatment resistant, or have medical conditions
wherein taking medications is contraindicated
[20]. Nonpharmacological treatments include
different types of nondrug modalities such as
transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and

placebo therapies, just to name a few, although
more research is needed to confirm the results
of these new treatment opportunities. TMS is a
noninvasive and safe technique that has been
utilized for over 30 years in many aspects of
neuroscience and medicine to treat depression,
movement disorders, and epilepsy, as well as
for rehabilitation [21, 22]. This method works
by applying a coil to the scalp that produces
a fluctuating magnetic field, inducing an ionic
current in the cortex. This approach alters the
firing pattern and excitability of cortical neurons
depending on the frequency [23]. TMS can be
used both diagnostically and therapeutically to
prevent and treat migraine [24]. In addition, tDCS
can be an effective, noninvasive, and painless
therapeutic modality for preventing and treating
migraine [25, 26]. It is a neuromodulation
technique, which is similar to repetitive TMS
(rTMS) and causes reversible alterations in neuron
excitability in cortical areas [27]. rTMS disrupts
or enhances the firing of neurons, whereas tDCS
modulates these firing rates by altering resting
membrane potential [28]. Other techniques that
are available include transcranial alternating
current stimulation, transcranial near-infrared
stimulation, functional electrical stimulation,
transcutaneous electrical nerve stimulation, pulsed
radio-frequency, peripheral nerve stimulation,
and electroacupuncture [29]. Meanwhile, numerous
placebo treatments for migraine offer safe and
alternative outcomes [30, 31]. However, similar to
the use of medication treatments, everyone will
not respond the same way to nonpharmacological
modalities.
Migraine can be divided into different subtypes
such as migraine with aura, migraine without
aura, migraine without head pain, hemiplegic
migraine, retinal migraine, chronic migraine,
vestibular migraine, and various headaches [32].
The classification of migraine into different
subtypes is important because the pathophysiology,
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mechanism, brain alterations, and treatment
approaches are quite different in these cases [32].
Furthermore, current research suggests that the
brains of migraineurs suffering from these subtypes
are significantly different in terms of structure
and function [33–36] owing to gender [37], age
[38, 39], genetic [40] and psychological makeup
[41], and causal variables, which make therapeutic
assignment complicated and difficult. Apart
from finding appropriate migraine medicaments,
interindividual differences associated with the
causal variables mentioned above make treating
migraine complicated. For example, most
migraineurs are females, whose specific migraine
treatments involve hormonal interplay [39, 42],
and even children are affected, thereby making
medical care more challenging [38, 43]. Targeted
therapy has numerous potential advantages,
including decreased exposure of patients to
medications that may be harmful or ineffective,
and reduced financial burden spent on those
remedies [44]. It is worth considering whether
there exist subtypes of migraine that might benefit
from targeted therapies based on the above causal
factors [45].
Neuroimaging studies have revealed multiple
structural and functional abnormalities in multiple
cortical and subcortical brain regions in association with migraine [46–52]. Advanced magnetic
resonance imaging (MRI) methods are helping to
improve our knowledge about brain alterations
in migraineurs. They can objectively measure
neuroimaging findings (quantitative biomarkers)
diagnostically and delineate therapeutic care
pathways [53]. Functional MRI (fMRI) is a useful
and noninvasive modality used to detect neural
changes associated with increased blood flow
when an area of the brain is being used either
at rest or during a task [54]. It can linearly track
within-person differences in migraine, providing
novel insights into the brain activity linked to pain
stimuli or other behaviors [36, 55–58]. Structural
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MRI uses strong magnetic fields, gradients, and
radio waves to generate images of the brain,
especially between gray matter (GM) and white
matter (WM) volume that identifies brain structural
alterations for many conditions of the central
nervous system, including demyelinating diseases,
dementia, cerebrovascular disease, infectious
diseases, Alzheimer’s disease, epilepsy [59], and
chronic pain [60]. Diffusion tensor imaging (DTI)
is another MRI technique that measures restricted
water diffusion in tissues to produce neural tract
images, and numerous brain abnormalities can
be detected by examining specific anisotropy and
diffusivity measures. Its fiber orientation and
strength estimation are very accurate, and it has
widespread potential implications in the fields
of cognitive neuroscience and neurobiology [61].
It also provides useful structural information for
detecting changes in WM tracts in patients with
chronic pain [62, 63]. These methods can be used
together in pain studies because each has its
unique strengths and practicalities. In this review,
we summarize neuroimaging modalities and
analyses associated with migraine and assess
selective causal factors of interindividual
differences among migraineurs, which would aid
in categorizing them into alternative nondrug
treatments.

2

Neuroimaging and migraine

Migraine is predominantly a brain function
disorder. Many researchers have focused on
analyses of functional connectivity to investigate
specific brain region organization/functional
networks in the pathophysiology of migraine,
including neural activation patterns in response
to painful or noxious stimuli [64–70], even in
children [71]. However, it is not necessary that
neurologically normal migraine patients be
subjected to undergo neuroimaging methods [68].
Instead, neuroimaging methods are recommended
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for migraineurs who have increased migraine
frequency, severity, or altered clinical characteristics, migraine with confusion, hemiplegic
migraine, and other serious conditions [68]. There
are also obvious structural changes in GM that
lead to migraine, especially in the cingulate,
frontal lobes, and limbic areas [72, 73]. Positron
emission tomography and single-photon emission
computed tomography were utilized to examine
the serotonergic system in migraineurs’ brains
[74] and the underlying mechanisms of sensory
hypersensitivity [75]. Since migraine attacks are
extremely unpleasant, neuroimaging during an
acute attack is rarely done. Thus, migraine imaging
experiments are mainly conducted during the
interictal phase [72].
When comparing migraine patients with healthy
controls, there was abnormal connectivity among
many brain regions involved in pain processing
[52, 76, 77], sensory-discriminative pain processing
(somatosensory cortex and posterior insula) [65,
78], affective emotional processing (anterior insula,
anterior cingulate cortex, and amygdala), cognitive
processing (hippocampus, parahippocampal gyrus,
and orbitofrontal cortex), and pain modulation
(periaqueductal gray area and nucleus cuneiformis) [76, 79–88]. One of the key theories from
these investigations is that there appears to be
an imbalance in pain signaling processing,
leading to hypersensitivities as well as a lack of
normal habituation in migraineurs; this is due to
poor inhibition of pain signaling pathways [64,
89]. Chronic pain, as defined by Apkarian et al.
in 2009, is “a state of continuous learning, which
has a close connection with an unconditionally
pain-related stimulus, without the opportunity
to disrupt the association with continuous pain”
[90]. This can be a chain of neural alterations from
autonomic, sensory, and disgust pathways that
create remnants of memory that alter the brain
structurally, leading to the formation of long-

term memory [91]. As migraine is characterized
by recurrent moderate-to-severe headaches,
functions of the brain may be constantly
reorganized during long-term migraine, so that
novel knowledge can be linked with functional
connectivity patterns between brain regions.
Other researchers have agreed that the generation
of migraine is beyond a neurovascular model
and involves a dysfunctional neurolimbic pain
network [92].
Additionally, researchers have discovered
alterations in resting-state functional connectivity
of the dorsal pons, brainstem, and hypothalamus,
as well as dopaminergic networks in migraineurs
[72]. Nagesh et al. found that the red nucleus and
substantia nigra were activated during migraine,
possibly owing to nociceptive and autonomic
dysfunction [93]. Several researchers imaged the
brainstem to study the mechanisms of chronic
migraine and found that the hypothalamus was
important in regulating the pathophysiology
during acute and chronic migraine [94–96]. Based
on the above findings, May suggested that the
pathophysiology and genesis of migraine attacks
are probably not just the result of a single “brain
stem generator” [97]. They pointed out that
spontaneous oscillations of complex networks
involving the hypothalamus, brainstem, and
dopaminergic networks lead to changes in
activity in certain subcortical and brainstem areas,
thus changing susceptibility thresholds and not
only starting but also terminating headache
attacks [97].
Another important model proposed by Borsook
et al. suggested that the insula plays a role in
migraine and other chronic pain conditions
because migraine is associated with a range of
sensory, emotional, and cognitive symptoms [98].
The insula can thus act as a cortical hub that
processes all this migraine input. Research has
indicated that migraine changes the activation of
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the insula and can even affect insular function
with long-term attacks [98].
Alternately, migraine occurrence may be
explained by a maladaptive feed-forward allostatic
cascade model and how it might lead to alternative courses of treatment [1]. Although migraine
is a recurring pain condition, it still utilizes
global synchronization in various pain-processing
functions, resulting in an abnormal transmission
network [7, 99, 100]. Borsook et al. proposed an
allostatic load model of migraine that explaine
how long-term and high-frequency migraine
attacks change normal physiological stability and
reinforce painful emotions [1]. They noted that
although stress can precipitate migraine onset, it
may lead to poor habituation [1] because emotions
and migraine-related pain perception are closely
associated [101]. In other words, when stress
becomes more frequent or intense, the allostatic
load, which pertains to use and abuse on all
physiological systems involved in stress adaptation, becomes irregular and poorly adapted
and completely changes the migraineurs’ neural
networks. This then results in an unbreakable
cycle of the brain’s poor response to repeated
stress, causing behavioral and physiological
changes that increase the allostatic load even
more [1].
There are also limitations in fMRI research,
including inadequate number of patients (limited
statistical power and significance), poor timing
intervals, and variability in methods and data
analysis. Few replication studies have been
conducted to confirm these results, and more
research is needed to increase the confidence
interval to establish the applicability of these
findings. Overall, additional fMRI investigation
is needed using whole-brain meta-analyses and
heterogeneity in analysis methods [64]. More
investigations should focus on neural regions
and networks associated with migraine and their
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interactions with causal factors, especially during
the ictal phase to further identify the specific
mechanisms of migraine. Additional longitudinal
studies must be conducted to better characterize
the effects of attack frequency and to assess
longitudinal changes in brain structure and
function related to migraine.

3

Factors of individual differences

3.1 Duration and pain intensity
As migraine duration increased, the main theory
was that the longer the headache attack lasted,
the more remarkable the abnormalities of painrelated information processing in migraine, which
may also mirror the properties of the clinical
conditions impacting brain functional network
organization. Liu et al. assessed the longitudinal
GM and WM changes between repeated
observations 1 year apart in a group of migraine
patients and found that they had decreased GM
in the dorsolateral part of the prefrontal cortex,
orbitofrontal cortex, and primary/secondary
somatosensory cortices at 1-year follow-up [102].
A cross-sectional study showed that subjects
with a longer duration of migraine had differences
in GM/WM density compared with those with
a relatively shorter time, and the authors inferred
that migraine may be associated with progressive
functional and structural changes in the brain
[103]. Understanding how the human brain is
reorganized during chronic migraine and its
relationship between GM/WM abnormalities can
significantly improve treatment approaches.
3.2 Age
The brain has various response mechanisms in
dealing with different stressors, which are age
dependent [104]. Stressful stimuli that are
encountered in early childhood may affect neural
stress circuits, causing changes in neuroendocrine
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phenotypes that become maladapted and result
in susceptibility to disease, including migraine,
and poor responses to treatment [105]. Migraines
cause significant problems in children, which
become more prominent after puberty [106].
Certain remedies can even affect cognitive and
executive function in children [107] and may even
modify allostatic load [1]. Chronic consequences
of migraine on the developing brain are not
completely understood, although early exposure
to stressful stimuli can change the “trajectory
of brain development”, especially in the frontal
regions and the amygdala [105].
3.3 Gender and hormones
Migraine has a much higher incidence and
prevalence in women than men, according to
epidemiologic evidence for sex-related differences
[108, 109]. It is affected by a lifetime of alterations
in sex hormones ranging from puberty to pregnancy to menopause. Migraines are believed
to be caused by decreased estrogen before
menstruation known as the “estrogen withdrawal
hypothesis” [110]. However, the effect of gender
has often been avoided in the clinical management of migraine [111]. Surprisingly, most
neuroimaging studies of migraineurs have been
predominantly female subjects, while the male
counterparts are understudied. There are
structural alterations in the insula and precuneus
in women who suffer from migraine [52] as
compared to men whose changes appear in
the parahippocampal gyrus [111]. Resting-state
networks of functional connectivity have been
reported to be abnormal in women during
migraine [79]. Female migraine patients have
increased connectivity between the default mode
network, central executive network, and insula
[85] due to possible sex-specific differences in
connectivity strength. Understanding these gender
differences may identify gender-specific pathways

for furthering new and effective medical development as well as improving research results
when controlling the menstrual cycle variables.
We feel that genetic research may help in
depicting how sex hormones affect migraine
pathophysiology.
3.4 Genetics
Generational and twin research distinctly showed
that migraine is a genetic disorder. There are
many common migraine gene variants, which
contribute to the subject’s disease susceptibility.
Initially, studies identifying gene variants using
linkage and association approaches by testing
genetic markers had limited success due to lack of
robustness (for review see [112]). One such linkage
study identified a migraine susceptibility locus
on chromosome 4q21–q24 [113]. Additionally,
researchers have found other loci (4q28, 17p13,
18q12) showing linkage with specific migraine
symptoms and traits (pulsing pain, light and
sound sensitivities, exercise overexertion, age at
onset, etc.) [114]. Their work revealed no gender
difference for 4q24, but there was one for loci
17p13 and 18q12. Another migraine susceptibility
locus was discovered on chromosome 10q22
[114]. Interestingly, the 10q22 locus could be a
“predominantly female-dominated inheritance
pattern” in linked Finnish families. There is
more research focusing on sex chromosomes.
For instance, migraine susceptibility loci were
located on the X chromosome at Xq24–q28 [115],
Xp21 [114] and Xp22 [116]. There are also
many genetic association studies that identified
DNA polymorphisms encoded in proteins from
migraine-relevant pathways in the serotonin
and dopamine systems [112]. One such study
identified DNA variations in the serotonin 5-HT
transporter gene that were associated with migraine in women [117]. Another study indicated
there were gender differences between C677T and
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migraine phenotypes [118]. Women with the
TT genotype were significantly associated with
unilateral migraine pain, and those with the
CT genotype displayed nausea and osmophobia
symptoms [118]. Catechol-O-methyltransferase
(COMT) Val158Met polymorphism is another
migraine-related trait that did not necessarily
exhibit pain vulnerability to migraine [119], but
interindividual differences in COMT activity
influenced clinical responses to migraine
medications [120]. COMT also affects hippocampal formation [121], which is involved in the
pathophysiological process of migraine formation.
It can be inferred that migraine and COMT
Val158Met may interact with the hippocampus
to create maladaptive stress in chronic pain
conditions. Another study showed that there
were interactions between COMT and structural
volumetric morphology of migraineurs’ brains
[40]. Although these genetic findings are interesting,
few of them have been replicated and even fewer
have been performed on each gender. Therefore,
at this time, it is difficult to rely on these initial
results and further investigation is needed.

4

Nonpharmacological treatments: TMS,
tDCS, and placebo

Finding an effective and beneficial migraine cure
is challenging by controlling predisposing factors
such as drug overuse. Central neuromodulation
methods include TMS [23–25, 122] and tDCS
[123]. Repetitive TMS seems to be the most
promising with a moderate amount of evidence
contributing to decreased migraine frequency,
duration, intensity, and impairment (for a comprehensive review on using TMS see [124]). One
such study used high-frequency rTMS on the
dorsolateral prefrontal cortex to treat chronic
migraine attacks frequency [125], and lowfrequency rTMS was no more effective in
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preventing migraine attacks [126]. TMS can also
be used to stimulate the visual cortex to modulate
phosphene thresholds in migraineurs [127].
Single-pulse TMS has only been utilized in episodic
migraine, but without conclusive results [25].
Compared to TMS, tDCS has fewer side effects,
is convenient and cheaper [128]. Anodal tDCS
is the most commonly used mode stimulating
the M1 area, and the cathode is placed on the
opposite supraorbital area (1–2 mA current
intensity for 15–20 minutes) [29]. Research has
demonstrated that anodal stimulation of the
dorsolateral prefrontal cortex, primary motor
cortex, and visual cortex may help decrease pain
in migraineurs [129–132]. Otherwise, sparse
research using tDCS in migraine did not show
that it had a significant effect on migraine
frequency compared with placebo [123], according
to findings by Auvichayapat et al. [133]. A couple
of tDCS studies reported negative results in
preventing migraine because the target brain area
was not yet determined. One study used tDCS
to stimulate the visual cortex, but there was no
decrease in migraine attacks or difference between
the two groups [123]. The other was a pilot study
that also demonstrated no significant difference
in the number of migraine attacks and the
intensity and duration between sham stimulation
and tDCS [26]. Overall, research using tDCS in
migraine prevention and treatment are contradictory due to poor selection of optimal
stimulation settings and brain areas.
Placebo analgesia is an effective therapeutic
method for migraine by controlling pain perception [134]. The outcomes of placebo can create
a treatment effect through certain expectations
or cues [135, 136] that engage neural and cognitive
processing [137]. Studies have shown that
endogenous opiate and dopamine circuits are
affected in placebo pain research [138, 139] and
that individual differences in these systems may
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be directly related to hypoalgesia [140]. Sham
acupuncture and surgery demonstrated a greater
decrease in migraine attacks than oral placebos
[30]. One sham acupuncture pain study showed
that psychological factors could decrease migraine
frequency and that baseline GM medial prefrontal
cortex volume could be used to predict future
placebo responses in migraine patients [60].
Central brain stimulation and placebo methods
have not been researched adequately to make
treatment recommendations for chronic migraine
and the results are highly variable. Some research
has indicated that insular activation is caused by
placebo although more imaging studies are
required to show the insula’s role in placebo
in migraineurs [98, 134, 141]. Their efficacy in
treating migraine has yet to be investigated in
large-scale, double-blinded, random controlled
experiments.
There are many limitations of TMS, tDCS, and
placebo therapeutics, especially with regard to
bias, insufficient blinding, and small, nonhomogeneous sample size. The most common problem
is dealing with the side effects of treatment. TMS
can result in headache, migraine, sinusitis, and
even has a rare incidence of seizures. The main
concern with TMS is overheating of the brain with
constant exposure, high intensity, and frequency
[23]. The potential side effects of tDCS are not
yet known [123]. As for placebo, the observed
effects might be due to nonspecific causes, and the
extent of these effects will be different, depending
on the techniques used [30].

5

Individual differences and their
relationship with migraine treatments

Recently, one depression study used fMRI to
classify depression patients into four neurophysiological subtypes or “biotypes” [142] based
on the neurophysiological differences in the
connectivity patterns in their brains [143]. These

biotypes were differentiated not only clinically
but mostly on various clinical symptom
descriptions, which would then predict whether
TMS would be an effective treatment [142].
Other predictive biomarkers may be utilized to
classify subjects depending on these biotypes,
and valuable diagnosis can be achieved using
guided therapy.
Since most migraineurs are not a homogeneous
group, significant individual differences exist
for particular cures. In this review, we searched
PubMed for works with the keywords “treatment
prediction and migraine” and found 48 related
articles dating back to 2006. We select and
summarize 14 pertinent studies which are
specifically related to interindividual differences
and treatment responses (Table 1).
According to a systematic review, migraineurs
had a 0–56% response rate to placebo modalities
[30]. Further evidence has shown that responses
to placebo treatment were initiated by the central
nervous system as well as through cognitive and
mood pathways [137]. Thus, the variability in
the treatment success of placebos may be linked
with the variations of migraineurs’ brain structure
and function. Recently, Liu et al. hypothesized
that interindividual variability in the migraine
brain could predict placebo hypoalgesia before
commencing clinical therapy [41, 60, 147]. They
reported that GM volume of the medical prefrontal
cortex (mPFC) and its functional connectivity at
baseline could predict placebo responses in an
8-week sham acupuncture treatment for migraine,
and that patients who had abnormal GM volume
of the amygdala were susceptible to persistent
headaches and diminished response to placebo
treatment [60]. Additionally, using DTI, they
further reported that the interindividual variations
of the WM tract microstructure of the mPFCamygdala may be a predisposition for subsequent
responses to placebo remedies in migraineurs
[147]. Further investigations into the individual
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Table 1 Individual differences and their relationship with migraine treatments.
Cohort
(n)

Treatment

Main findings

Barad et al.
(2019) [144]

402

Response to botulinum toxin A in
a migraine cohort with multiple
comorbidities

Developed a migraine prophylaxis therapy (PREEMPT)
protocol to examine longitudinal treatment responses and
assess predictors of treatment effectiveness

Bravo et al.
(2019) [145]

173

Botox treatment for migraine

Utilized data mining techniques to predict Botox treatment
effectiveness based on different causal factors

Kisler et al.
(2019) [146]

55

Migraine treatment with duloxetine

Migraine patients with increased pronociceptivity before
treatment experienced more analgesic effects

Liu et al.
(2019) [147]

124

8-week sham acupuncture treatment
for migraine

Interindividual variability of the white matter tract
microstructure of the medial prefrontal cortex-amygdala
may be a predisposition for subsequent responses to placebo
treatment in migraineurs

Gago-Veiga et
al. (2019) [148]

34

Measured premonitory symptoms
of migraine to assess the patients’
capability to predict these attacks and
allow better response to therapy.

Few patients were reliable predictors based on interindividual differences, but the identification of premonitory
symptoms was significantly accurate to make treatment
more effective

Liu et al.
(2017) [41]

71

8-week sham acupuncture treatment
for migraine

Interindividual variability in the migraine brain could
predict placebo hypoalgesia before commencing clinical
treatment.

Liu et al.
(2017) [60]

196

8-week sham acupuncture treatment
for migraine

Patients who had abnormal GM volume of the amygdala
had susceptibility to persistent migraine and diminished
response to placebo treatment.

Lipton et al.
(2016) [149]

8233

Acute migraine medication

Predicted inadequate responses to acute migraine
treatment using predictors related to sociodemographics,
migraine features, comorbidities, and treatment profiles

Pagán et al.
(2015) [150]

2

Standard migraine treatments

Used hemodynamic measurements to predict and
effectively treat migraine attacks

Büchel et al.
(2014) [137]

Review

Placebo treatments for migraine

Responses to placebo treatment were initiated by the central
nervous system as well as through cognitive and mood
pathways

Meissner et al.
(2013) [30]

Review

Placebo treatments for migraine

Sham acupuncture and surgery achieved a greater reduction
in migraine frequency than oral drug placebos

Migraine treatment with duloxetine

No significant result

Migraine treatment with triptans

Analyzed gene polymorphisms, personality characteristics,
and migraine traits to develop a scoring system for predicting treatment outcome. Migraineurs with lower scores
had a lower risk for not responding to triptan treatment

Migraine treatment with triptans and
placebo

No significant result

Reference

Young et al.
(2013) [151]

22

Ishii et al.
(2012) [152]

60

Maas et al.
(2008) [153]

1288

differences of placebo analgesia and effects of
other nonpharmacological intervention in chronic
pain are warranted to potentially improve
treatment strategies and also to be able to develop
more efficient clinical trials.
Another significant study showed that personalizing medical care could be used to design
a suitable migraine prevention program via
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psychophysical testing to characterize pronociceptive patients that would respond better
to serotonin-norepinephrine reuptake inhibitors
[146]. It was concluded that patients with increased
pronociceptivity prior to treatment experienced
more analgesic effects. Other studies relating to
this had insignificant results because of poor
experimental design [151, 154].
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A study relating to nonresponders who received
migraine treatment with triptans analyzed gene
polymorphisms, personality characteristics, and
migraine traits to develop a scoring system for
predicting treatment outcome [152] as compared
to previous studies by Maas et al. [153, 155].
Migraineurs with lower scores had a decreased
risk for not responding to triptan medication
[152]. This scoring system still needs a larger
sample size to be considered valid. Furthermore,
having the knowledge that certain migraine
patients will respond better to preventive treatment
can be useful in both clinical and research settings.
Hence, future research on bigger cohorts may
determine the ideal pain sensitivity levels for
migraineurs.
One study developed a migraine prophylaxis
therapy (PREEMPT) protocol to examine
longitudinal treatment responses and assess
predictors of effectiveness in patients with multiple
overlapping pain disorders [144]. They assessed
responses to botulinum toxin A. After 3 months
of therapy, decreased migraine attacks appeared
in 62% of the subjects. Similarly, another research
group utilized data mining techniques to predict
Botox effectiveness in migraineurs based on
different causal factors [145]. They were able to
utilize certain classifiers and clustering methods
to predict decreased migraine attack frequency
and treatment side effects with a relatively high
accuracy. Gago-Veiga et al. were even able to
measure premonitory symptoms (PSs) of migraine,
which occur before migraine onset, and use them
to assess the patients’ capability to predict these
attacks and allow better response to therapy
in 2018 [148]. However, very few patients
were reliable predictors based on interindividual
variability since there was no definite baseline
characteristic, but the identification of PSs was
significantly accurate to make treatment more
effective [148].

Another important study predicted inadequate
responses to acute migraine medications using
predictors related to sociodemographics, migraine
features, comorbidities, and treatment profiles
of individual patients [149]. This retrospective
study provided a limited understanding of the
therapeutic outcome predictors related to specific
medications and interindividual covariates.
However, it was relevant in detecting the unmet
needs in migraine subgroups experiencing
inadequate responses to acute treatment [149].
A study has calculated individual differences
of hemodynamic measurements such as heart
rate, skin temperature, electrodermal activity,
and peripheral capillary oxygen saturation, and
associated these measurements with efficiency
of clinical outcomes [150]. The models could
predict the onset of migraine 52 minutes prior to
the attack, so that treatment response would be
more effective. This type of study is still in the
exploratory stage and must be applied to a much
larger cohort of migraine subjects as well as tested
with different migraine causal factors.

6

Conclusions and future research

Migraine is a complicated disorder with various
causal factors and interindividual differences
that make treatment complicated. Specific brain
structural variability at baseline could depict
subjects with pain disorders that would respond
to therapy. Future research is warranted regarding
longitudinal studies on causal factors of migraine,
new techniques used to treat migraineurs, and
emphasis on the importance of considering
interindividual differences when conducting
research studies and treating migraine patients.
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